Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen:
Volltext verfügbar? / Dokumentlieferung
doi:10.22028/D291-37695
Titel: | Impact of neoadjuvant chemotherapy on survival and recurrence patterns after robot-assisted radical cystectomy for muscle-invasive bladder cancer : Results from the International Robotic Cystectomy Consortium |
VerfasserIn: | Gopalakrishnan, Dharmesh Elsayed, Ahmed S. Hussein, Ahmed A. Jing, Zhe Li, Qiang Wagner, Andrew A. Aboumohamed, Ahmed Roupret, Morgan Balbay, Derya Wijburg, Carl Stöckle, Michael Dasgupta, Prokar Khan, Muhammad Shamim Wiklund, Peter Hosseini, Abolfazl Peabody, James Shigemura, Katsumi Trump, Donald Guru, Khurshid A. Chatta, Gurkamal |
Sprache: | Englisch |
Titel: | International Journal of Urology |
Bandnummer: | 29 (2022) |
Heft: | 3 |
Seiten: | 197-205 |
Verlag/Plattform: | Wiley |
Erscheinungsjahr: | 2021 |
Freie Schlagwörter: | bladder cancer chemotherapy muscle-invasive neoadjuvant oncological outcomes recurrence recurrences robot-assisted radical cystectomy survival |
DDC-Sachgruppe: | 610 Medizin, Gesundheit |
Dokumenttyp: | Journalartikel / Zeitschriftenartikel |
Abstract: | Objectives To analyze the impact of neoadjuvant chemotherapy on survival and recurrence patterns in muscle-invasive bladder cancer after robot-assisted radical cystectomy. Materials and methods The International Robotic Cystectomy Consortium database was reviewed to identify patients who underwent robot-assisted radical cystectomy for muscle-invasive bladder cancer between 2002 and 2019. Survival outcomes, response rates, and recurrence patterns were compared between patients who received neoadjuvant chemotherapy and those who did not. Survival distributions were estimated using Kaplan–Meier analyses and compared using the log-rank test. Results A total of 1370 patients with muscle-invasive bladder cancer were identified, of whom 353 (26%) received neoadjuvant chemotherapy. After a median follow-up of 27 months, neoadjuvant chemotherapy recipients had higher 3-year overall survival (74% vs 57%; log-rank P < 0.01), 3-year cancer-specific survival (83% vs 73%; log-rank P = 0.03), and 3-year relapse-free survival (64% vs 48%; log-rank P < 0.01). Neoadjuvant chemotherapy was a predictor of higher overall survival, cancer-specific survival, and relapse-free survival in univariate but not multivariate analysis. Pathological downstaging (46% vs 23%; P < 0.01), complete responses (24% vs 8%; P < 0.01), and margin negativity (95% vs 91%; P < 0.01) at robot-assisted radical cystectomy were more common in the neoadjuvant chemotherapy group. Neoadjuvant chemotherapy recipients had lower distant (15% vs 22%; P < 0.01) but similar locoregional (12% vs 13%; P = 0.93) recurrence rates. Conclusions In this analysis from a large international database, patients with muscle-invasive bladder cancer who received neoadjuvant chemotherapy before robot-assisted radical cystectomy had higher rates of survival, pathological downstaging, and margin-negative resections. They also experienced fewer distant recurrences. |
DOI der Erstveröffentlichung: | 10.1111/iju.14749 |
URL der Erstveröffentlichung: | https://onlinelibrary.wiley.com/doi/10.1111/iju.14749 |
Link zu diesem Datensatz: | urn:nbn:de:bsz:291--ds-376954 hdl:20.500.11880/34100 http://dx.doi.org/10.22028/D291-37695 |
ISSN: | 1442-2042 0919-8172 |
Datum des Eintrags: | 25-Okt-2022 |
Bezeichnung des in Beziehung stehenden Objekts: | Supporting Information |
In Beziehung stehendes Objekt: | https://onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1111%2Fiju.14749&file=iju14749-sup-0001-Supinfo.docx |
Fakultät: | M - Medizinische Fakultät |
Fachrichtung: | M - Urologie und Kinderurologie |
Professur: | M - Prof. Dr. Michael Stöckle |
Sammlung: | SciDok - Der Wissenschaftsserver der Universität des Saarlandes |
Dateien zu diesem Datensatz:
Es gibt keine Dateien zu dieser Ressource.
Alle Ressourcen in diesem Repository sind urheberrechtlich geschützt.